Premium
Pentoxifylline fails to attenuate fibrosis in dystrophic ( mdx ) diaphragm muscle
Author(s) -
Gosselin Luc E.,
Williams Jacqueline E.
Publication year - 2006
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.20523
Subject(s) - pentoxifylline , duchenne muscular dystrophy , diaphragm (acoustics) , muscular dystrophy , medicine , hydroxyproline , diaphragm muscle , fibrosis , mdx mouse , skeletal muscle , dystrophin , endocrinology , respiratory system , physics , acoustics , loudspeaker
Fibrosis is a common pathological feature observed in muscle from patients with Duchenne muscular dystrophy and in mdx diaphragm. The purpose of this study was to determine whether pentoxifylline (PTX) treatment for 4 weeks (16 mg/kg/day) could significantly attenuate the process of fibrosis in diaphragm muscle from mdx mice. PTX treatment had no impact on in vitro diaphragm muscle contractile function. In addition, diaphragm muscle hydroxyproline concentration and the level of type I and III collagen and TGF‐β1 mRNA were unaffected by PTX treatment. These findings do not support the use of PTX as an antifibrotic drug for the treatment of muscular dystrophy. Muscle Nerve, 2006